In summary, the incidence of KRAS (32.4% vs. 10.1%, p < 0.001) and SETD2 (10.5% vs. 1.4%, p = 0.001) gene mutations was substantially higher in 11q23/KMT2A‐rearranged AML pediatric patients than non‐11q23/KMT2A‐rearranged AML pediatric patients. This evidence concerns the gene KRAS and acute myeloid leukemia.